- Is bird flu going to affect human flu vaccine production? (cnbc.com)
sunny side (up) to the major avian flu outbreak that is squeezing the nation's egg supply,..You'll still be able to get your flu vaccine this fall,.."Eggs used to manufacture FluMist/Fluenz are not affected by the egg shortage." …eggs used to produce those vaccines come from "specific pathogen-free chickens which are housed in entirely separate sites and facilities from chickens used for the food supply,"....
- CVS: ‘all bets are off’ for new cholesterol drug contracts (newsdaily.com)
CVS Health Corp, the No 2 manager of drug benefit plans for U.S. employers and insurers, will wait until a second new cholesterol-lowering drug is approved by regulators before negotiating for price discounts or adding either of the much pricer new drugs to its list of covered medications.
- Allergan taps purple-haired millennial mascot for hashtag-heavy women’s health push (fiercepharmamarketing.com)
Newly reinvented Allergan is looking to women’s health as a core therapeutic area, and millennial women make up a large part of its target audience. So now, it’s rolling out a new campaign focused specifically on reaching that population–and it’s using hashtags, emojis and a purple-haired heroine to do it...#ActuallySheCan
- Pharma leaves ad agencies behind for in-house digital marketing teams (fiercepharmamarketing.com)
Brands are ditching agencies and bringing digital marketing in-house in bigger numbers than ever, and that includes pharma companies… inability of agencies to break through decades of organizational history to respond to fast-changing needs," Pharma does differ …is generally behind on social is due to regulatory concerns…. this is starting to change,"
- AstraZeneca bags another cancer drug deal, this time with Inovio (newsdaily.com)
AstraZeneca (MedImmune) has clinched its third deal in less than a week to bolster it…cancer drug pipeline by signing up rights to an experimental immune system-boosting medicine from Inovio Pharmaceuticals… will get $27.5 million upfront and potential future payments of up to $700 million, depending on the success of its INO-3112 immunotherapy, which targets cancers caused by human papillomavirus...
- International Academy of Compounding Pharmacists Podcast #15: Jay McEniry & David Miller Discuss Tricare (iacprx.org)
Podcast interview with..David G. Miller, RPh, International Academy of Compounding Pharmacists Executive Vice President, and Jay McEniry, Executive Director, Patients and Physicians for Rx Access...topic is Tricare, and the current issues facing compounding pharmacists, and most importantly, the patients they serve.
- Amarin wins injunction against FDA in free speech case (fiercepharma.com)Amarin case could unleash a flood of off-label promos (fiercepharmamarketing.com)
Amarin won what was being called a First Amendment free speech victory for drugmakers. It got a federal court to say the FDA cannot bar Amarin from discussing off-label use of its fish-oil drug Vascepa for a wider group of patients than it is approved for…not clear how big a victory the ruling will be given it came in a lawsuit Amarin brought against the FDA as a defensive move.